Results 71 to 80 of about 179,498 (360)

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

Cancer Research, 2005
Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients, relapses have been observed and are much more prevalent in ...
T. O'hare, D. Walters, Eric P. Stoffregen, Taiping Jia, P. Manley, J. Mestan, S. Cowan-Jacob, F. Lee, M. Heinrich, M. Deininger, B. Druker   +10 more
semanticscholar   +1 more source

Single‐Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang, Norzawani Buang, Catherine Sutherland, Wanseon Lee, Lauren Overend, Tarran S. Rupall, Katie L. Burnham, Matthew C. Pickering, Marina Botto, Emma E. Davenport   +9 more
wiley   +1 more source

Partial Inhibition of Epithelial-to-Mesenchymal Transition (EMT) Phenotypes by Placenta-Derived DBMSCs in Human Breast Cancer Cell Lines, In Vitro

Cells
Stem cell-based therapies hold significant potential for cancer treatment due to their unique properties, including migration toward tumor niche, secretion of bioactive molecules, and immunosuppression.
Yasser Basmaeil, Abdullah Al Subayyil, Haya Bin Kulayb, Altaf A. Kondkar, Maha Alrodayyan, Tanvir Khatlani   +5 more
doaj   +1 more source

BCR/ABL1 Fusion Protein [PDF]

, 2020
National Cancer Institute
openalex   +1 more source

T Cell Plasticity in Systemic Lupus Erythematosus Revealed by Large‐Scale T Cell Receptor Repertoire and Transcriptome Studies

Arthritis &Rheumatology, EarlyView.
Objective We aimed to characterize CD4+ T cell plasticity in human systemic lupus erythematosus (SLE) by leveraging T cell receptor (TCR) repertoire features as markers of prior lineage states, integrating TCR and transcriptomic profiling to delineate plasticity patterns and evaluate their association with clinical disease activity. Methods We used TCR
Yasuo Nagafuchi, Masahiro Nakano, Kaitlyn A. Lagattuta, Mineto Ota, Hiroaki Hatano, Haruka Takahashi, Takahiro Itamiya, Hajime Inokuchi, Soumya Raychaudhuri, Tomohisa Okamura, Keishi Fujio, Kazuyoshi Ishigaki   +11 more
wiley   +1 more source

BCR-ABL1 and beyond [PDF]

, 2020
Susan Branford
openalex   +1 more source

Enzymatic synthesis of acylglycerides from agroindustrial residues: process design and simplified techno‐economic assessment

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract This study developed an enzymatic process to add value to palm oil fatty acid distillate (PFAD) and glycerol, resulting in the production of monoacylglycerides (MAG) and diacylglycerides (DAG). The biocatalyst loading (Novozym 435) and molar ratio of reagents were evaluated to obtain a suitable reaction condition in terms of space–time yield ...
Ronaldo Rodrigues de Sousa, Isabelle de Souza Barbosa, Ana Cristina de Araújo Collaço, Denise Maria Guimarães Freire, Viridiana Santana Ferreira‐Leitão   +4 more
wiley   +1 more source

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Cancer Cell, 2014
Summary Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph+) leukemia, including the recalcitrant BCR-ABL1T315I mutant.
M. Zabriskie, C. Eide, S. Tantravahi, N. Vellore, Johanna Estrada, F. Nicolini, H. Khoury, R. Larson, M. Konopleva, J. Cortes, H. Kantarjian, E. Jabbour, S. Kornblau, J. Lipton, D. Réa, L. Stenke, G. Barbany, T. Lange, J. Hernández-Boluda, G. Ossenkoppele, R. Press, C. Chuah, S. Goldberg, M. Wetzler, F. Mahon, G. Étienne, M. Baccarani, S. Soverini, G. Rosti, P. Rousselot, Ran Friedman, Marie Deininger, K. R. Reynolds, W. Heaton, A. Eiring, A. Pomicter, J. Khorashad, T. Kelley, R. Baron, B. Druker, Michael W. Deininger, T. O'hare   +41 more
semanticscholar   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Association of Clinical Features and Hematological Laboratories between Ph (+)/BCR-ABL (+) Chronic Myeloid Leukemia and Other Type of Ph/BCR-ABL Chronic Myeloid Leukemia

Jurnal Penyakit Dalam Indonesia, 2018
Introduction. Patients with chronic phase Chronic Myeloid Leukemia (CML) at Hematology-Medical Oncology Clinic Department of Internal Medicine dr. Cipto Mangunkusumo National Hospital who haveperformed cytogenetic and RTPCR BCR-ABL examination showed: Ph
Wulyo Rajabto, A. Harryanto, Hilman Tadjoedin, Kuntjoro Harimurti   +3 more
doaj   +1 more source